JAZZ PHARMACEUTICALS: IN CONNECTION WITH ACTIO BIOSCIENCES ACQUISITION, ESTIMATES Q3 2026 GAAP & NON-GAAP PRE-TAX IPR&D CHARGE OF $755 MLN

Reuters · 4d ago

Please log in to view news